AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.
Status:
Recruiting
Trial end date:
2023-07-24
Target enrollment:
Participant gender:
Summary
This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and
expansion study including an intra-participant ramp-up.
AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to
participants with relapsed/refractory haematological malignancies.